Ovarian cancer cells express both estrogen receptor a (ERa) and ERb, and hormonal therapy is an attractive treatment option because of its relatively few side effects. However, estrogen was previously shown to have opposite effects in tumors expressing ERa compared with ERb, indicating that the two receptor subtypes may have opposing effects. This may explain the modest response to nonselective estrogen inhibition in clinical practice. In this study, we aimed to investigate the effect of selectively targeting each ER subtype on ovarian cancer growth. Ovarian cancer cell lines SKOV3 and OV2008, expressing both ER subtypes, were treated with highly selective ER modulators. These results were confirmed on a xenograft model where SKOV3 cells were injected s.c. into ovariectomized mice. We observed that the average size of xenografts in both the DPN-treated group and the MPP-treated group was significantly smaller than that for the vehicle-treated group. In addition, we found that phospho-AKT expressions in SKOV3 cells were reduced by 80% after treatment with MPP and DPN, indicating that the AKT pathway was involved. The combined treatment with MPP and DPN had a synergistic effect in suppressing ovarian cancer cell growth. Our findings indicate that targeting ER subtypes may enhance the response to hormonal treatment in women with ovarian cancer.
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Introduction
Ovarian cancer is the fifth commonest cancer in women in western countries (Siegel et al. 2011) . Primary treatment largely consists of cytoreductive surgery followed by adjuvant chemotherapy. However, despite optimal treatment, recurrences are common and the overall prognosis is poor. A number of second-line chemotherapy regimes are available, achieving an overall response rate of about 20-30%, while producing significant side effects. Hormonal therapy would be an attractive treatment option because of its minimal side effects and relative ease of administration. Theoretically, ovarian cancer is a hormone-sensitive tumor. Previous studies have shown that the expression of estrogen receptors (ERa and ERb) was detectable in 60-100% of ovarian cases and estrogen was shown to increase tumor cell proliferation in ovarian cancer cell lines (Lindgren et al. 2004 , De Stefano et al. 2011 . However, tamoxifen, a well-established selective ER modulator (SERM) for treatment of breast cancer, produces only a modest response rate of 10-15% in ovarian cancer (Perez-Gracia & Carrasco 2002) . One of the key issues is how to improve its effectiveness. For many years, estrogen has been known to act through ERs. In 1996, a new ER (ERb) was discovered and was found to be genetically distinct from the classical ER (ERa) (Kuiper et al. 1996) . Since then, ERb has been found in most estrogen-target tissues such as the prostate (Weihua et al. 2001 ) and the ovary (Brandenberger et al. 1998) . Reduced levels of ERb mRNA expression were found in malignant tissues compared with normal tissues in various estrogendependent tumors such as breast, prostate, and ovarian cancers (Iwao et al. 2000 , Horvath et al. 2001 , Skliris et al. 2003 , Chan et al. 2008 , indicating that the loss of ERb expression may be involved in carcinogenesis. This is further supported by the findings that ectopic expression of ERb in breast, prostate, and ovarian cancer cells inhibits motility and cell invasion and leads to increased apoptosis (Lazennec et al. 2001 , Cheng et al. 2004 . In breast cancer cells, estrogen increased cell proliferation in the presence of ERa but in the presence of ERb it inhibited proliferation (Strom et al. 2004) . As the activation of each subtype may lead to opposing effects, the overall effect may be compromised by the relative expression of the ER subtypes in individual tumors. In this study, we explored the effects of estradiol (E 2 ), 4-hydroxytamoxifen (4-OH Tam), a SERMs, and fulvestrant (Ful), a pure estrogen antagonist, on cell proliferation after individually knocking down each receptor subtype in two ovarian cancer cell lines that express both receptor subtypes. In addition, we also attempted to explore the possibility of improving hormonal response by using highly selective agonists and antagonists that only bind to one subtype. We treated ovarian cancer cells with highly selective ERa and ERb agonists and antagonists and determined their effects on cell growth. We then attempted to confirm these findings using in vivo nude mice model and elucidate the molecular pathway involved.
Materials and methods

Chemicals
The 
Cell culture
The ovarian epithelial cancer cell lines OV2008, C13, A2780S, A2780CP (gifts from Prof. B K Tsang, Department of Obstetrics and Gynaecology, University of Ottawa), SKOV3, and OV326 and the breast cancer cell lines MCF7 and T47D (purchased from the American Type Cell Collection, Rockville, MD, USA) were used in this study (Sasaki et al. 2000 , Asselin et al. 2001 . Authentication of the cell lines was carried out by short tandem repeat profiling to confirm the cell of origin. Cells were cultured in MEM medium (Gibco, Invitrogen) supplemented with 10% fetal bovine serum (Gibco) and antibiotics (50 U/ml penicillin and 50 mg/ml streptomycin) (Gibco). Four days before the experiment, the cultures were switched to phenol-red-free MEM medium (Gibco) supplemented with 10% charcoaldextran-treated fetal bovine serum (HyClone, Thermo Fisher Scientific, Waltham, MA, USA) and antibiotics. All cells were cultured at 37 8C in a humidified atmosphere of 95% air and 5% CO 2 . Cells were routinely subcultured when they reached 80% confluency.
Cell proliferation assay
Cells were plated at an initial concentration of 1200 cells/well of 96-well plate in full medium or phenol-redfree medium. The next day, cells were washed with PBS and then subjected to treatment with various concentrations of SERMs for 96 h. Cell proliferation was measured every 24 h using sodium 3 0 -[1-(phenylaminocarbonyl)-3,4-tetrazolium]-bis(4-methoxy-6-nitro) benzene sulfonic acid hydrate (XTT) assay (Roche Diagnostics) according to the manufacturer's protocol. Briefly, XTT labeling mixture was prepared by mixing XTT solution (1 mg/ml) with electron coupling reagent at a ratio of 50:1. Culture medium was discarded and cells were washed with PBS. About 100 ml PBS and 50 ml XTT labeling mixture were added to each well and the 96-well plate was incubated at 37 8C for 4 h. 
Western blotting
For the examination of AKT activity, ovarian cancer cells (SKOV3) treated with vehicle solution DMSO, MPP (100 pM), DPN (10 nM), or a combination of MPP and DPN at different time points (0, 4, and 24 h) were collected using a cell scraper and washed in cold PBS. To examine the expression of estrogen-responsive genes, SKOV3 cells were treated with DMSO, MPP (100 pM), DPN (10 nM), or a combination of MPP (100 pM) and DPN (10 nM) in the absence or presence of E 2 (10 nM) for 24 h. Collected cells were lysed with NET lysis buffer containing 0.2% NP40, 10 mg/ml each of aprotinin and leupeptin, and 1 mM phenylmethylsulfonyl fluoride. Proteins were analyzed by western blotting using antibodies including anti-ERa (sc-8002, Santa Cruz), anti--ERb (sc-8974, Santa Cruz), AKT, p-AKT (Ser473) (Cell Signaling, Danvers, MA, USA), cyclin D1 (Santa Cruz), HER2 (Epitomics, Inc., Burlingame, CA, USA), p21 (Santa Cruz), EGFR (Cell Signaling), FBLN-1 (Santa Cruz), and HRPconjugated secondary antibody, and detected with ECL. Total cell lysates were also blotted with b-actin (Sigma) or GAPDH (Sigma) antibodies as a loading control. Experiments were carried out at least twice to confirm the results.
Statistical analysis
The Prism Software Package (GraphPad Software, Inc., San Diego, CA, USA) was utilized for statistical analysis.
For the XTT assay, data are expressed as optical density and are meanGS.D. of determinations from a single experiment that was repeated three times. The results, whenever applicable, were analyzed by two-tailed Student's t-test to determine if significant differences (P!0.05) had been observed.
Results
Conventional hormonal treatment of with E 2 , 4-OH Tam, and Ful mainly acts via ERa in ovarian cancer cell lines
Western blotting was carried out to evaluate the protein expressions of ERa and ERb. We confirmed that SKOV3 and OV2008 cells expressed both ERa and ERb proteins (Fig. 1A) . Since the sensitivity of specific antibodies might affect the band intensity in western blotting, the results obtained might not reflect the protein abundance for ERa and ERb expression. We then evaluated the actual copy number of ERa and ERb by quantitative real-time PCR in SKOV3 and OV2008 cells. We found that the copy number of ERa after normalization with the internal control gene TBP was 401 and 101 in SKOV3 and OV2008 respectively (Fig. 1B) . The copy number of ERb was seven in both SKOV3 and OV2008. Therefore, the ERa:ERb ratio of SKOV3 is 57:1 and that of OV2008 is 14:1. We investigated the effective dose of E 2 , 4-OH TAM, and Ful on SKOV3 cell proliferation by XTT assay with various dosages of hormonal drugs. We found that 10 nM of E 2 significantly increased cell proliferation (P!0.001, Student's t-test) while both 4-OH Tam (P!0.05, Student's t-test) and Ful (P!0.01, Student's t-test) reduced cell proliferation at the minimum dosages of 100 nM (Fig. 1C) . We then examined cell proliferation with the same dosages of E 2 , 4-OH Tam, and Ful in OV2008 (Fig. 1D ). Similar results were obtained. These results indicated that both OV2008 and SKOV3 responded to conventional hormonal drug action. To investigate whether the hormonal drugs exerted their action through ERs, SKOV3 cells were then transfected with negative control siRNA (NTC), ERa-targeting siRNAs, or ERbtargeting siRNAs in order to knockdown the expression of individual receptor subtype. Expressions of ERa and ERb were evaluated by western blot analysis after siRNA transfection and the band intensity was quantified using a densitometer. ERa and ERb siRNAs profoundly reduced ERa and ERb expression respectively by w70 and 90% in SKOV3 cells relative to the control (NTC) siRNA and nontransfected cell (Kve) ( Fig. 2A and B) . To determine the effect of these drugs in the absence of ERa subtype, cells transfected with ERa siRNAs were treated with E 2 , 4-OH Tam, and Ful. The stimulatory effect of E 2 on cell growth was significantly abolished after ERa silencing (Fig. 2C, PZ0 .0044, Student's t-test). The inhibitory effects of 4-OH Tam (Fig. 2D, PZ0 .0152, Student's t-test) and Ful were significantly abolished (Fig. 2E, PZ0 .0023, Student's t-test). The effects of these drugs were then investigated in the absence of ERb in cells transfected with ERb siRNAs. The stimulatory effect of E 2 on cell growth remained unchanged (Fig. 2C) while the inhibitory effects of 4-OH Tam and Ful were slightly reduced in ERb-silenced cells ( Fig. 2D and E) . These results indicated that the effects of E 2 , 4-OH Tam, and Ful were mainly mediated via ERa.
The effects of highly selective SERM treatment on cell growth in ovarian cancer cell lines
We first examined the effects of highly selective SERMs on cell growth of ovarian cancer cells with ERa and ERb expression in normal MEM medium supplemented with 10% fetal bovine serum. SKOV3 cells were treated with different dosages of SERMs and the effects on cell growth were evaluated by XTT assay. We found that 100 pM of PPT (ERa agonist, P!0.02, Student's t-test) and PHTPP (ERb antagonist, P!0.01, Student's t-test) significantly increased cell proliferation while both MPP (ERa antagonist, P!0.02, Student's t-test) and DPN (ERb agonist, P!0.004, Student's t-test) significantly reduced cell proliferation at the minimum dose of 100 pM and 10 nM respectively (Fig.  3A) . In addition, to test whether these SERMs are effective in the absence of ERa and ERb expression, cell proliferation of ovarian cancer cell line A2780S (with no ERa and ERb expression) was also examined with SERM treatment under the same condition. Notably, no significant stimulatory or inhibitory effect on cell proliferation was observed after SERM treatment (Fig. 3B) . These results indicated that SERMs are only effective in ERa-and ERb-expressing cell lines. To examine whether the effects of SERMs were also valid in media with reduced levels of hormones, SKOV3 was then cultured in phenol-red-free MEM medium (Gibco) supplemented with 10% charcoal-dextran-treated fetal bovine serum before the experiment. Cell proliferation was evaluated with or without SERM treatment in SKOV3. XTT assay revealed that treatments with MPP or DPN also significantly suppressed growth of the cells. Furthermore, treatment with PPT or PHTPP significantly enhanced ovarian cancer cell growth in SKOV3 cells (Fig. 4A) . These results indicated that SERMs exert their stimulatory or inhibitory effects even under very low levels of hormones in ovarian cancer cells. To confirm that the effects of SERMs were not cell-line-specific, another ovarian cancer cell line OV2008, expressing both ERa and ERb, was chosen for further investigation in phenol-red-free MEM medium (Gibco) supplemented with 10% charcoal-dextran-treated fetal bovine serum. Similar effects of SERMs on cell proliferation were observed in OV2008 cells (Fig. 4B) .
The suppressive effects of MPP and DPN treatment are mediated by ERs
In order to determine if the effects of highly selective SERM treatment were mediated by the particular ERs, we employed siRNA specifically targeting ERs in SKOV3 cells. After siRNA transfection, the cell viability assay was carried out to evaluate the effects of SERMs on cell growth in ERaor ERb-silenced cells. We found that knockdown of ERa significantly reduced the response to MPP (Fig. 4C , P!0.05, Student's t-test) and showed higher cell viability as compared with NTC siRNA-transfected cells even with MPP treatment. Also, knockdown of ERb also significantly diminished the suppressive effect of DPN on cell growth (Fig. 4D , P!0.05, Student's t-test). These results implied that the inhibition of ovarian cancer cell growth by MPP or DPN was regulated by targeting to their specific ERs.
MPP and DPN treatments reduce in vivo tumor cell growth in mice
By in vitro XTT assay, we observed a drastic effect on cell growth for MPP and DPN. Next, we sought to investigate whether MPP and DPN exhibit the same effect in vivo. We established a xenograft model by s.c. injection of SKOV3 cell into ovariectomized mice. Mice bearing xenografts of 5 mm diameter received vehicle solution, MPP (1 mg/kg per day) or DPN (1 mg/kg per day), by an i.p. injection. We observed that the average size of xenografts in both the MPP-treated group (P!0.0001, Wilcoxon's rank-sum test) and the DPN-treated group (PZ0.0005, Wilcoxon's ranksum test) was significantly smaller than that for the vehicle-treated group (Fig. 5A) . These results indicated that MPP and DPN also exert an inhibitory effect on ovarian cancer growth in vivo.
Combined treatment with MPP and DPN synergistically suppress ovarian cancer cell growth
To see whether the combination of MPP and DPN could enhance the inhibitory effects on ovarian cancer cell growth compared with single-SERM treatment, we carried out the XTT assay on SKOV3 treated with DMSO (control), MPP alone (100 pM), DPN alone (10 nM), and MPP (10 pM)CDPN (10 pM). As expected, the growth rate was inhibited following either MPP or DPN single treatment. Combined treatment with MMP and DPN showed greater growth inhibition than either treatment alone. In addition, lower concentrations of each SERM were required to produce the inhibitory effect (Fig. 5B) Effect of estrogen receptor status on drug efficacy. SKOV3 cells were transfected with negative control (NTC) siRNA, ERa-or ERb-targeting siRNA and treated with drugs for 48 h. siRNA1 and siRNA2 are two different siRNAs targeting the same gene. The expression of (A) ERa and (B) ERb was confirmed by western blot using anti-ERa and anti-ERb antibodies 72 h after siRNA transfection respectively. The values below the blots represent the change in protein expressions of the siRNA-transfected cells normalized to the expression in the NTC siRNA-transfected cells. After siRNA transfection, the cell viability of SKOV3 cells was measured by XTT assay after treatment with (C) E 2 (100 nM), (D) 4-hydroxytamoxifen (100 nM), and (E) fulvestrant (100 nM) for 48 h. Growth was compared with the mock-treated controls (DMSO).
that combined treatment with MPP and DPN enhanced the inhibitory effect on ovarian cancer cell growth.
MPP and DPN treatment alter the expression of estrogen-responsive genes
To examine the effects of SERM treatment on the expression of estrogen-responsive genes, the protein expressions of cyclin D1, HER2, p21, EGFR, and FBLN-1 were examined by western blot. We found that two of the examined genes EGFR and FBLN-1 showed altered protein expression in SERMs-treated cells in the presence of E 2 . In vehicle-treated SKOV3 cells, the addition of E 2 induced the expression of EGFR and FBLN-1 by 2.1-and 9.8-fold respectively (Fig. 6 ). The addition of MPP, DPN, or combined SERM treatment (MPPCDPN) suppressed the expressions of EGFR and FBLN-1 induced by E 2 (Fig. 6) .
No observable alterations were found in the protein expressions of cyclin D1, HER2, and p21 in E 2 -and SERM-treated cells. 
MPP and DPN suppress AKT activity in SKOV3 cells
To test whether ERs mediate nongenomic pathway in ovarian cancer cells, SKOV3 was treated with vehicle solution (DMSO), MPP, DPN, or MPPCDPN at different time points (0, 4, and 24 h). We investigated whether treatment of SERMs on ERs involved the inactivation of the AKT signaling pathway. Treatment with SERMs suppressed p-AKT expression without modifying the levels of total AKT (Fig. 7) . The level of p-AKT expression was reduced by 20 and 80% after treatment with MPP for 4 and 24 h respectively. Similar observations were found in DPN-treated SKOV3 cells. DPN treatment reduced p-AKT expression by 10% (4 h) and 80% (24 h). Notably, reductions of 20% (4 h) and 90% (24 h) of p-AKT expression were detected with combined MPP and DPN treatment. No obvious alteration was observed in vehiclesolution-treated cells after 24 h. As the phosphorylation of serine 473 in AKT is an activating phosphorylation of the AKT protein, these results indicated that the AKT activity in SKOV3 cells was suppressed by MPP and DPN.
Discussion
With about 60% of tumors expressing ERs, ovarian cancer was believed to be a hormone-responsive tumor. The initial findings showed that estrogen enhances cell proliferation while tamoxifen, an antiestrogen, was shown to suppress tumor cell proliferation. Tamoxifen has been in clinical use in the treatment of ovarian cancer for over 15 years. However, the overall response rate was only about 10% (Williams et al. 2010) . These initial findings had not taken into account the presence of ER subtypes. Both ERa and ERb were found to be present in both normal ovarian tissues and ovarian cancer tissues, with a possible reduction of ERb expression as tumors progress (Bardin et al. 2004a , Chan et al. 2008 . The loss of ERb expression indicates that ERb exerts tumor-suppressive functions and may have a protective role. Similar findings were reported in other hormone-responsive tissues such as breast, colon, and prostate (Skliris et al. 2003 , Bardin et al. 2004b . In this study, we first attempted to confirm the previously reported effects of E 2 and 4-OH Tam in two ovarian cancer cell lines, SKOV3 and OV2008, which express both ERa and ERb. Receptor subtype status of SKOV3 had been controversial in the literature. SKOV3 was reported to be ERa-negative and ERb-positive (Treeck et al. 2006) and it had also been described as estrogenunresponsive because it expresses a dysfunctional ERa and very low levels of ERb (Jones et al. 1994 , Lau et al. 1999 . However, we demonstrated by western blotting that SKOV3 expressed both receptors, although the expression of ERa was higher than that of ERb in the ratio of 57:1 by quantitative real-time PCR, which is compatible with the findings of O'Donnell et al. (2005) and we demonstrated that this cell line was responsive to estrogen. The use of a cell line that has high ERa:ERb ratio has the advantage that it may better reflect the clinical situation where ERb expression is lower than that of ERa in ovarian cancer tissue samples. Nonetheless, it also has the disadvantage that it is difficult to completely isolate the effects of individual receptor subtypes by siRNA gene-silencing experiments because it is not possible to achieve a 100% knockdown rate.
Our findings confirmed that E 2 stimulated-while 4-OH Tam inhibited ovarian cancer cell growth in these two cell lines as seen in previous reports (Langdon et al. 1990 (Langdon et al. , 1994 . Our initial gene-silencing experiment results also agreed with previous reports that the action of estrogen and 4-OH Tam was mainly via ERa (O'Donnell et al. 2005) . In addition, our results also indicated that Ful also mainly acted via ERa. However, the apparent lack of effect from ERb in the gene-silencing experiments maybe due to the incomplete knockdown of ERb. With the knockdown rate of about 80% in a cell line SKOV3 with a 57:1 ERa:ERb ratio, even when 80% of ERa is knocked down, the final effect may still be a result of both receptor subtypes.
In order to circumvent this issue, we used highly selective agonists and antagonists for each receptor subtype and we found that ERb activation led to inhibition of ovarian cancer cell growth in SKOV3. This agrees with previous findings where the overexpression of ERb1 ligand was associated with antitumoral effects on ovarian cancer cells (Treeck et al. 2007) . In order to show that these results are not cell-line-specific, we repeated the experiment with another ovarian cancer cell line OV2008 where there was a ERa:ERb ratio of 14:1. Even with this very low relative ratio of ERb, the inhibitory effect of ERb agonist was still evident. A previous report showed that DPN did not produce any effect on cell proliferation until it reached a high concentration of 1 mM where it might start to crossreact with ERa (O'Donnell et al. 2005) . In our experiments, however, we found that even at a concentration as low as 10 nM, DPN produced significant growth inhibition and the effect appeared to be dose-dependent. Furthermore, gene silencing with siRNAs for individual receptor subtypes confirmed that these effects were mediated via the respective receptors, without significant cross-reaction with the other subtype. The molecular pathways involved in the activation of ERa are well reported but the pathways involved in ERb activation are much less well established (Drummond & Fuller 2010) . Therefore in this study, we also attempted to elucidate the molecular pathways involved. Both genomic and nongenomic pathways are known to mediate the effects of ERa and we anticipate that these pathways would also be involved in the activation of ERb. We evaluated the effect of SERM treatment in regulating gene transcription of estrogen-responsive genes. Expressions of EGFR and FLBN-1 were increased in E 2 -treated SKOV3 cells. Addition of MPP, DPN, or a combination of MPP and DPN suppressed the protein expressions of EGFR and FBLN-1 induced by E 2 . Our result indicated that SERM treatment of ovarian cancer cells might also be involved in the regulation of transcription of estrogen-responsive genes.
In addition, we also investigated the effects of SERM treatment on the nongenomic pathway. As AKT mediates a variety of cellular responses and plays a central role in oncogenic transformation by blocking apoptosis and stimulating cell growth, we attempted to examine whether binding of ERa antagonist and ERb agonist could also suppress the phosphorylation of AKT in ovarian cancer cells expressing ERs. We found that suppression of ERa by MPP or stimulation of ERb by DPN treatment dramatically suppressed the expression of p-AKT in SKOV3 cells. With the role of AKT in activating cell growth, the suppression of p-AKT expression by MPP or DPN treatment may contribute to the inhibition of cell proliferation of ovarian cancer cells. Involvement of other nongenomic pathways and the upstream and downstream targets should be further explored in a subsequent study.
Apart from ovarian cancer, ERb has been implicated in the carcinogenesis of various other malignancies including prostate cancer (Attia & Ederveen 2012) , colorectal cancer (Castiglione et al. 2008) , and cholangiocarcinoma (Marzioni et al. 2012) . The development of very selective ERb agonists has been very promising in recent years (Mohler et al. 2010) . There is increasing evidence in recent years that ERb may have a tumor suppressor function in different tumors. In breast cancer, ERb agonist was found to arrest angiogenesis and tumor growth in mouse xenograft models . Selective ERb agonists have also been shown to reduce hepatoma, gliomas, and medulloblastoma growth (Zhou et al. 2010 , Mancuso et al. 2011 , Sareddy et al. 2012 . Each cell type has different cofactors and coregulators and the effect of receptor activation might be different and hence tissuespecific. The exact ERb agonistic effects on ovarian tumors have not been reported, but previous studies have indicated a role for ERb in ovarian cancer. Zhu et al. (2011) reported that reexpression of ERb inhibits the proliferation of ovarian clear cell adenocarcinoma cells. Apart from its potential use in tumor suppression, the use of selective ERb agonist has also been investigated in different diseases. ERb agonist alleviated the chronic inflammatory pain state and was suggested to represent a novel way of addressing neuropathies (Gardell et al. 2008) . Its anti-inflammatory effect may even attenuate atherogenesis . ERb has also been implicated in brain function and aging (Foster 2012 , Handa et al. 2012 . It was shown to have anxiolytic and antidepressant effects, which may be useful in affective disorders (Hughes et al. 2008) . ERb agonist was also shown to improve survival in animal models of severe sepsis due to its protective effects on gastrointestinal barrier function (Cristofaro et al. 2006) . Furthermore, a selective ERb modulator, MF101, has been shown to reduce menopausal symptoms in phase 2 clinical trials (Grady et al. 2009 , Stovall & Pinkerton 2009 ).
Our findings indicate that there may be a role for these highly selective SERMs in the treatment or prevention of ovarian cancer. Our previous study showed that ERb expression in clinical samples decreased from normal tissue to borderline tumors to malignant tumors. The tumor-suppressor effects in ovarian cancer may be beneficial in various clinical situations. Its clinical effectiveness in reducing hot flushes in menopausal symptoms together with its tumor-suppressive effects in ovarian cancer may provide a safe option for 'hormone replacement therapy' in younger women who have undergone hysterectomy and bilateral oophorectomy for the treatment of ovarian cancer. The abundance of ERb expression in borderline tumors may indicate that selective ERb agonists could be a potential treatment option in borderline ovarian tumors, which are typically chemoresistant. In malignant ovarian clinical samples, especially at the advanced stage, ERb expression is reduced. Nonetheless, we demonstrated a significant effect on reduction of cell proliferation in our cell lines where there was a very low ERa:ERb ratio. This indicated that ERb agonist may still be beneficial even in the presence of relatively low ERb expression.
Optimizing the response to hormonal treatment may offer a good treatment option. Various strategies had been explored. Blockage of production of E 2 by blocking the aromatase or sulfatase pathways by aromatase inhibitors was tried but only with limited success (Papadimitriou et al. 2004 ). This may be partially explained by the intratumoral production of E 2 that can enhance tumor growth (Suzuki et al. 2008) . Blocking the E 2 receptors would also counteract the intratumoral production, but the use of antiestrogens such as 4-OH Tam and Ful (Argenta et al. 2009 ) only showed a poor response. Targeting the ER subtypes by using an ERb agonist with or without an ERa antagonist in women with known ER subtype status may offer a new option. The response may be further enhanced when combined with aromatase inhibitors. Future studies on animal models and the molecular mechanisms involved would be required to further explore this possibility.
